No controlled human trial of topical NAD+ or NMN with skin endpoints has been published. The formulation literature exists because the molecule penetrates poorly.
Restore the cellular fuel your skin loses with age — topical NAD+ to switch repair back on at the mitochondrial level.
The market's own words. No brand is named, because the claim is the thing under examination and it belongs to dozens of them.
In adults with visible skin aging, does a topical NAD+ or NMN preparation, compared with vehicle, produce measurable change in any skin endpoint — and does the molecule reach living skin from a topical application at all?
The same claim written as a proposition somebody could go and check: who, compared with what, measured how, over how long.
What kind of missing this is
The mechanism is sound in a dish. The step where the ingredient reaches the layer of skin that matters, at the amount actually in the bottle, is the step nobody has shown.
There is no clinical study to describe, so the interesting thing is what is there instead — and what is there is a body of formulation research.
The published literature on topical NMN is largely about how to get it into skin: liposomal nanogels, delivery systems, permeation work. That literature exists for a reason. Nobody builds a nanogel for a molecule that crosses the stratum corneum easily. The delivery research is, in effect, a standing acknowledgement by the field that the delivery problem is not solved, published alongside products sold as though it were.
The rest is cell-culture work — fibroblast transcriptomics, effects on cultured cells at concentrations achieved by putting the compound directly into the medium. That is a legitimate first step and it is not a skin result. Cells in a dish have no barrier.
The one randomized trial with a skin-adjacent endpoint that turned up is of oral nicotinamide riboside, for cutaneous nerve regeneration, and it was negative. Different route, different question, and it does not support the topical claim in either direction.
One trial is now running. NCT07774000, sponsored by ChromaDex, is a randomized, quadruple-masked, placebo-controlled study of topical nicotinamide riboside on facial skin aging, 140 participants estimated, twelve weeks, which began recruiting on 17 August 2026. It has not reported.
That trial reporting, and reporting in enough detail to be useful: NCT07774000 is a placebo-controlled 140-person study with a twelve-week endpoint, which is exactly the shape of thing this claim needs. A clear positive would move this entry to Partially established — for topical nicotinamide riboside specifically, at whatever concentration and vehicle it used, which is a narrower claim than the one on the bottles and the entry would say so.
Separately and more fundamentally: a human permeation study showing that topical NAD+ or NMN reaches the viable epidermis at a measurable concentration from a cosmetic vehicle. Without that, no efficacy trial can be interpreted, because a positive result would be as likely to belong to the vehicle as to the active.
Until either exists, this stays where it is. And note the trial is company-sponsored, which does not disqualify it — it does mean that if it reports positive, the second, independent trial becomes the interesting one.
It does not mean NAD+ biology is nonsense. It is one of the better-founded areas in aging research, and the cell-level rationale here is real rather than invented.
It does not mean niacinamide is unproven. Niacinamide is a different, cheaper, well-evidenced ingredient with a substantial topical literature, and the similarity of the names does an enormous amount of unearned work in this category.
It does not mean the serum on your shelf does nothing at all. It is a serum. It contains a vehicle, humectants and probably several other actives with their own evidence, and it may be perfectly good for reasons unrelated to the molecule on the front.
And it does not mean this will be true next year. There is a trial running. This is the entry in the register most likely to move next.
You are paying a premium — often a substantial one — for an ingredient with no published human skin data and an unsolved delivery problem, in a product whose other ingredients are the ones with the evidence.
What you are not paying for is a demonstrated topical effect, because there isn't one yet, and the company running the trial to find out has been recruiting for less than a month.
The practical version: if a NAD+ serum costs roughly what a good niacinamide serum costs, buy whichever you prefer and lose nothing. If it costs four times as much, the difference is being charged for the molecule, and the molecule is the part nobody has tested on skin.
Worth checking the ingredient list before you decide anything. A number of products in this category list niacinamide high and the NAD precursor low, which means the evidence-backed ingredient is doing the work and the unproven one is doing the marketing.
Type and funding are stated because they change what a study is allowed to prove, and because a trial paid for by the company selling the thing is not disqualified — it is just not the same evidence as one that was not.